This research study is currently not recruiting patients.

A Phase 2 study of WEE1 Inhibition with AZD1775 alone or combined with Cytarabine in Patients with advanced Acute Myeloid Leukemia Myelodysplastic Syndrome and Myelofibrosis

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Acute Myeloid Leukemia, Myelodysplastic Syndrome And Myelofibrosis
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Untreated elderly (>60 years) AML if in the intermediate and poor-risk cytogenetic group 2) Relapsed or refractory AML (=18 years) 3) Any MDS (=18 years) having failed or been intolerant to prior hypomethylating agent (HMA) treatment. 4) Advanced progressive MF, defined as intermediate and high risk primary and secondary MF, or any other MF failed or intolerant to JAK2 inhibitor therapy requiring medical therapy

You may not be eligible for this study if the following are true:

  • 1) Uncontrolled intercurrent Illness Including, but not limited to, active uncontrolled Infection, known positive for active infectious hepatitis, type A, B or C (past infection allowed), Note: ongoing infection controlled on antibiotics/antifungal/antiviral medications are allowed. 2) Cytotoxic Chemotherapy, Immunotherapy, Biologic therapy (i.e, antibody therapies), Radiation therapy 14 days prior to registration 3) Major surgery < 28 days prior to registration 4) Active uncontrolled CNS leukemia.